WO2025104123 - HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS
National phase entry is expected:
Publication Number
WO/2025/104123
Publication Date
22.05.2025
International Application No.
PCT/EP2024/082247
International Filing Date
13.11.2024
Title **
[English]
HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS
[French]
DÉRIVÉS HÉTÉROCYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS DE JANUS KINASE
Applicants **
CHIESI FARMACEUTICI S.P.A.
Inventors
ACCETTA, Alessandro
CUZZOLIN, Alberto
ELENKOV, Ivaylo Jivkov
MESIĆ, Milan
RADOŠEVIĆ, Ela
Priority Data
23210435.6
16.11.2023
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2244 | |
| EPO | Filing, Examination, Granting | 9261 | |
| Japan | Filing, Examination, Granting | 2086 | |
| South Korea | Filing, Examination, Granting | 1836 | |
| USA | Filing, Examination, Granting | 8340 |
Total:
23,767
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention relates to compounds that are cyclic carbamate and ureas benzo-morpholine and benzo-thiomorpholine derivatives of general formula (I) inhibiting the JAK family of non-receptor tyrosine protein kinases (JAK1, JAK2, JAK3, and TYK2); methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of the JAK family non-receptor kinases; in particular for the treatment of various inflammatory disease including asthma, COPD and other respiratory diseases.[French]
La présente invention concerne des composés qui sont des dérivés de carbamate cyclique, de benzo-morpholine et de benzo-thiomorpholine de formule générale (I) inhibant la famille JAK de protéines tyrosine kinases non réceptrices (JAK1, JAK2, JAK3 et TYK2) ; des procédés de préparation de tels composés, des compositions pharmaceutiques les contenant et leur utilisation thérapeutique. Les composés selon l'invention peuvent être utiles dans le traitement de maladies ou d'affections associées à une dysrégulation des kinases non réceptrices de la famille JAK ; en particulier pour le traitement de diverses maladies inflammatoires, notamment l'asthme, la BPCO et d'autres maladies respiratoires.